NCT06021509View on ClinicalTrials.gov

Clinical Study of NovoClasp for Treating Moderate to Severe and Severe Degenerative Mitral Regurgitation

NAActive, not recruitingINTERVENTIONAL

Enrollment

102

Participants

Timeline

Start Date

May 15, 2022

Primary Completion Date

June 25, 2024

Study Completion Date

June 25, 2028

Conditions

Degenerative Mitral Valve Disease

Interventions

DEVICE

NovoClasp® transcatheter mitral valve clip and steerable guide catheter

The experimental device is a class III implanted valve device, which will be used to treat the mitral valve regurgitation via transcatheter edge-to-edge repair.

Trial Locations (1)

Unknown

Beijing Anzhen Hospital, Capital Medical University, Beijing

All Listed Sponsors

lead

Enlight Medical Technologies (Shanghai) Co., Ltd

INDUSTRY